Results 211 to 220 of about 710,185 (341)

Diagnostic implications and correlates of plasma ADA2 activity and ADA2 variants

Arthritis &Rheumatology, Accepted Article.
Objectives Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2
Jian Yue, Courtney E. LeSon, Casey A. Rimland, Kailey Brodeur, Rachel Weng, Evan E. Hsu, Michael T. Lam, Manpreet Meyer, Seigo Okada, Andrew L. D. Hsu, Musaab A. Alhezam, Megan M. Perron, Olha Halyabar, Fatma Dedeoglu, Peter A. Nigrovic, Akiko Shimamura, R. Grant Rowe, Megan A. Cooper, Tiphanie P. Vogel, Miriah Gillispie‐Taylor, Rosemary Peterson, Clara Lin, Katherine D. Nowicki, Kaylee Dollerschell, Taizo A. Nakano, Roxane Labrosse, Alexis‐Virgil Cochino, Andreea Ioan, Leonardo Oliveira Mendonca, Samar Freschi Barros, Jorge Kalil, Javier Perez Rojas, Alicia Diaz Kuan, Eric S. Sobel, Taha Moussa, Samuel Shang Ming Lee, Li Wearn Koh, Archana Khan, Sodality Sutnga, Raju Khubchandani, Walaa Shoman, Yasmine El Chazli, Benzeeta Pinto, Chengappa Kavadichanda, Roshini S. Abraham, Xiangwei Sun, Qing Zhou, GSRSNK Naidu, Aman Sharma, Carl Esperanzate, Daniel L. Kastner, Ivona Aksentijevich, Susan J. Kelly, Michael Hershfield, Teresa K. Tarrant, Pui Y. Lee   +55 more
wiley   +1 more source

Correction of Tricuspid Regurgitation in Pulmonary Arterial Hypertension. [PDF]

JACC Case Rep
Orlando A, Vergara A, Naeije R, D'Alto M.   +3 more
europepmc   +1 more source

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database

Arthritis &Rheumatology, Accepted Article.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's Phenomenon (RP) and to explore their potential pathophysiological mechanisms through a mixed disproportionality/clustering analysis from the WHO pharmacovigilance database.
Alex Hlavaty, Loubna Dari, Jean‐Luc Cracowski, Matthieu Roustit, Charles Khouri   +4 more
wiley   +1 more source

The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases [PDF]

, 2013
Abdala, Ana P, Burchell, Amy, Engleman, Zoar J, Fudim, Marat, Gourine, Alexander V, Hart, Emma C J, Lobo, Mel, Marina, Nepthali, McBryde, Fiona D, Nightingale, Angus, Patel, Nik, Paton, Julian F R, Ratcliffe, Laura E K, Sobotka, Paul A   +13 more
core   +1 more source

Lupus-Associated Pulmonary Arterial Hypertension: A Success Story. [PDF]

JACC Case Rep
Gregório C, Abrantes A, Cazeiro DI, Guimarães T, Fontes T, Dourado E, Pinto FJ, Plácido R.   +7 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Mechanisms of cognitive impairment in arterial hypertension. [PDF]

World J Psychiatry
Kotlyarov SN.
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. [PDF]

Can Respir J
Lim L, Hansen D, Fairley J, Tabesh M, Ross L, Ferdowsi N, Ngian GS, Apostolopoulos D, Sahhar J, Host LV, Walker J, Major G, Proudman S, Stevens W, Nikpour M.   +14 more
europepmc   +1 more source

Trends in first‐line monotherapy and combination therapy for hypertension in UK primary care

British Journal of Clinical Pharmacology, EarlyView.
Aims Debate remains about the optimal initial treatment strategy for hypertension. Most guidelines recommend first‐line combination therapy for most patients. However, the UK's National Institute for Health and Care Excellence recommends first‐line monotherapy for all patients.
Kyle Johnson, Sarah Beradid, James M. Brophy, Robert W. Platt, Christel Renoux   +4 more
wiley   +1 more source